drugset / Trial / NCT05160272
Effects of GABAA Receptor Modulation by AP-325 on Insulin Secretion in Patients with Type 2 Diabetes
Phase 2
Completed
38 enrolled
The Deutsche Diabetes Forschungsgesellschaft e.V.
Algiax Pharmaceuticals GmbH · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The aim of this single-center, prospective, randomized, double-blind, placebo-controlled, 2-arm parallel-group interventional study is to investigate the effect of 4-week treatment with AP-325 on C-peptide release as measure of insulin secretion compared to placebo in type 2 diabetes (T2D) patients.
Timeline
- Start
- 2022-01-07
- Primary completion
- 2024-12-17
- Completion
- 2024-12-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AP-325 | Unknown | 50 mg | — |